Overt Hepatic Encephalopathy Market By Type, (Cover, Overt), By Treatment (Lactulose, Antibiotics, Probiotics, Branched-Chain Amino Acids, Liver Transplantation, Others), By Application (Hospitals, Research Institutes, Clinics, Surgical Centers) , By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2024-2033
-
42831
-
Jan 2024
-
182
-
-
This report was compiled by Trishita Deb Trishita Deb is an experienced market research and consulting professional with over 7 years of expertise across healthcare, consumer goods, and materials, contributing to over 400 healthcare-related reports. Correspondence Team Lead- Healthcare Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Quick Navigation
- Overt Hepatic Encephalopathy Market Size, Share, Trends Analysis
- Driving Factors
- Restraining Factors
- Overt Hepatic Encephalopathy Market Segmentation Analysis
- Overt Hepatic Encephalopathy Industry Segments
- Growth Opportunities
- Overt Hepatic Encephalopathy Market Regional Analysis
- Overt Hepatic Encephalopathy Market Key Player Analysis
- Overt Hepatic Encephalopathy Industry Key Players
- Overt Hepatic Encephalopathy Market Recent Development
- Report Scope
The Overt Hepatic Encephalopathy Market was valued at USD 52.16 million in 2022. It is expected to reach USD 112.3 million by 2032, with a CAGR of 8.18% during the forecast period from 2023 to 2032.
The surge in demand for non-pharmacological interventions and advanced treatments is one of the main driving factors for the overt hepatic encephalopathy market. Overt hepatic encephalopathy is a common reversible neurological dysfunction of cirrhosis. Liver cirrhosis leads to death and is a major threat globally. Cirrhosis is the last stage of chronic liver disease. It is one of the main diseases that cause death.
According to a report published by Frontiers in August 2022, the number of death cases related to liver cirrhosis has increased by 47.15%; however, the age-standardized mortality rate (ASR) of deaths is caused by the hepatitis C virus (HCV), consuming alcohol, and non-alcoholic steatohepatitis (NASH), which surged with an estimated annual percentage change (EAPC) of 0.17, 0.20, and 1.00, respectively.
Moreover, according to the National Library of Medicine, there are more than 2 million deaths each year, and 4% of all (1 out of every 25 deaths globally) are caused by liver-related disease, and approximately 2/3 of deaths are seen in men. Such types of chronic liver diseases fall under the grade 2-4 category of overt hepatic encephalopathy, which is life-threatening, and grade 1 is generally known as overt H.E.
Overt hepatic encephalopathy is seen in 30 to 40% of individuals who are suffering from cirrhosis, and in 10 to 50% of individuals, they have transjugular intrahepatic portal system shunts. According to the International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus in 2023, the start of perplexity or asterixis is the beginning of overt H.E. Some of the individuals with hepatic encephalopathy have elusive symptoms that may only be seen by using specialized tests and diagnosis. Such a condition is known as minimal hepatic encephalopathy, which is seen in almost 80% of the individuals suffering from cirrhosis.
Overt hepatic encephalopathy can be avoided or slowed down by adhering to proper treatment, specifically, treatment of liver disease, avoiding consumption of alcohol, avoiding medications such as sleeping pills and anti-depressants, regular liver function tests, and most importantly, following a nutritious diet. Xifaxan is a type of oral tablet that is advised by doctors for the treatment of liver diseases. It contains the drug rifaximin, which belongs to the antibiotic drug category. It is helpful for the overt H.E. of adults. The cases of overt hepatic encephalopathy will increase due to the high level of alcohol consumption and chronic liver disorders; this will spur market expansion in the forecast period.
Driving Factors
Rising Awareness Enhances Disease Understanding
The increasing public and medical community awareness regarding hepatic encephalopathy is a critical driver for its market growth. As understanding and recognition of this liver-related brain disorder improve, more individuals are seeking early diagnosis and treatment. Educational campaigns and medical conferences are shedding light on symptoms and treatment options, leading to earlier intervention and management strategies. This heightened awareness is expected to continue promoting the market's growth as more patients and healthcare providers recognize the importance of addressing this condition promptly.
Liver Disease Knowledge Spurs Treatment Demand
Growing knowledge about liver diseases and their complications, including overt hepatic encephalopathy, is driving the market's expansion. As the medical community and the public become more informed about the consequences of liver dysfunction, there is a heightened focus on monitoring and treating related conditions. This increased awareness is leading to more frequent screenings and a higher diagnosis rate of liver conditions that can progress to hepatic encephalopathy, subsequently boosting the demand for effective treatments and management strategies.
Lifestyle Factors Impact Disease Prevalence
The rise in alcohol consumption and smoking is a contributing factor to the growth of the overt hepatic encephalopathy market. These lifestyle choices are known risk factors for liver disease, which can lead to hepatic encephalopathy. As alcohol use and smoking rates increase globally, the prevalence of liver-related health issues also rises, leading to a greater need for hepatic encephalopathy treatments. Addressing the growing incidence of conditions caused by these lifestyle factors is crucial, and as such, the market is expected to expand as healthcare systems respond to this rising need.
Restraining Factors
Limited Availability of Treatment Options for Low-Income Individuals Restrains Overt Hepatic Encephalopathy Market Growth
The growth of the overt hepatic encephalopathy market is significantly limited by the restricted availability of treatment options for low-income individuals. Many of the treatments for hepatic encephalopathy, including medications, liver transplants, and ongoing care, are expensive and may not be covered by basic health insurance in many regions.
This financial barrier makes it difficult for low-income patients to access the necessary care, leading to untreated or inadequately treated cases. The inability of a significant portion of the affected population to afford these treatments limits the overall market growth and demand for therapeutic products and services.
Lack of Understanding of Clinical Courses and Relevance Limits Overt Hepatic Encephalopathy Market
The overt hepatic encephalopathy market also faces limitations due to a lack of understanding of the disease's clinical courses and relevance among healthcare providers and patients. Hepatic encephalopathy is a complex condition with varied presentations and a multifaceted clinical course. Inadequate knowledge and understanding of the disease among healthcare professionals can lead to underdiagnosis or misdiagnosis, inappropriate treatment approaches, and poor management of the condition.
Additionally, patients and their families might not recognize the early signs of the disease or understand the importance of adhering to treatment regimens, which can adversely affect treatment outcomes. Enhancing education and awareness about hepatic encephalopathy's clinical aspects is crucial for improving diagnosis, treatment, and market growth.
Overt Hepatic Encephalopathy Market Segmentation Analysis
By Type
Covert hepatic encephalopathy is the dominant segment within the hepatic encephalopathy market. This form of the condition is characterized by subtle neurological and psychiatric abnormalities often detected only through neuropsychological testing. The high prevalence of covert hepatic encephalopathy, along with its challenging diagnosis, underscores the need for increased awareness and improved diagnostic tools.
The management of covert hepatic encephalopathy is crucial in preventing progression to the more severe overt stage, which can have significant impacts on quality of life and require more intensive treatment. While covert remains the dominant segment, overt hepatic encephalopathy is also significant, characterized by more pronounced neurological and psychiatric symptoms and requiring immediate medical attention.
By Treatment
Lactulose stands as the dominant segment for treatment in the overt hepatic encephalopathy market. This non-absorbable disaccharide is widely used as a first-line treatment due to its effectiveness in reducing blood ammonia levels, a primary factor in the development of hepatic encephalopathy. Lactulose works by acidifying the contents of the colon, which helps trap ammonia and facilitates its excretion. The efficacy, availability, and relative safety of lactulose contribute to its dominance in the treatment of hepatic encephalopathy.
Other treatments, such as antibiotics, probiotics, branched-chain amino acids, and liver transplantation, also play crucial roles in managing the condition. Antibiotics are used to reduce ammonia-producing bacteria in the gut, while probiotics aim to restore healthy gut flora. Branched-chain amino acids can help improve cognitive function, and liver transplantation is considered in severe cases.
By Application
Hospitals are the dominant application segment in the overt hepatic encephalopathy market. They provide comprehensive care, including diagnosis, treatment, and management of the condition. The multidisciplinary approach available in hospitals is essential for the complex care needs of hepatic encephalopathy patients.
As the primary centers for emergency and intensive care, hospitals are crucial in managing overt episodes of the condition. Research Institutes, Clinics, and Surgical Centers also contribute to the market, each playing a role in understanding, diagnosing, and treating hepatic encephalopathy. Research institutes drive advancements in treatment, clinics offer ongoing management of the condition, and surgical centers are involved in procedures like liver transplantation.
Overt Hepatic Encephalopathy Industry Segments
By Type
- Cover
- Overt
By Treatment
- Lactulose
- Antibiotics
- Probiotics
- Branched-Chain Amino Acids
- Liver Transplantation
- Others
By Application
- Hospitals
- Research Institutes
- Clinics
- Surgical Centers
Growth Opportunities
Increasing Adoption of Precision Medicine Propels Overt Hepatic Encephalopathy Market
The increasing adoption of precision medicine offers significant growth opportunities in the overt hepatic encephalopathy market. Precision medicine approaches, which tailor treatment based on individual patient characteristics, are becoming more prevalent in managing complex conditions like hepatic encephalopathy.
As our understanding of the disease's pathophysiology improves, so does the ability to develop targeted therapies that can more effectively manage its symptoms and progression. This trend is leading to more personalized, effective treatment options and is driving demand for innovative therapies in the market, reflecting a robust growth potential as treatments become more individualized.
Strategies by Key Players Enhance Growth in Overt Hepatic Encephalopathy Market
Strategic initiatives undertaken by market players - partnerships, mergers & acquisitions, R&D investment, and geographic expansion - are driving growth in the overt hepatic encephalopathy market. Companies are increasingly investing in developing new treatments and expanding their reach to new markets and patient populations.
These strategies not only drive competition but also lead to the introduction of improved treatment options and increased accessibility for patients. This proactive approach by market players is a significant driver of growth, as companies seek to meet the evolving needs of the healthcare market and capitalize on emerging opportunities.
Overt Hepatic Encephalopathy Market Regional Analysis
North America Dominates with 71.00% Market Share in Overt Hepatic Encephalopathy Market
North America's significant 71.00% share of the overt hepatic encephalopathy market is largely driven by the region's high prevalence of liver diseases, including cirrhosis, which is a primary cause of hepatic encephalopathy. The United States, in particular, has a robust healthcare system with advanced medical facilities and significant investments in liver disease research and treatments.
Leading pharmaceutical companies operating in the region that specialize in developing and marketing treatments for hepatic encephalopathy also contribute to its high market share. Additionally, the increasing awareness about liver health and the availability of specialized medical care plays a crucial role in market dominance.
The market dynamics in North America are influenced by the region's strong emphasis on healthcare innovation and the availability of various treatment options, including medications and liver transplants. The increasing healthcare expenditure and insurance coverage for liver diseases lead to better access to treatments for hepatic encephalopathy.
Europe: Advanced Healthcare Systems and Research Initiatives
Europe’s overt hepatic encephalopathy market is driven by the region's advanced healthcare systems and strong research initiatives. The presence of well-established healthcare infrastructure, combined with high awareness about liver diseases, supports the demand for hepatic encephalopathy treatments. The market benefits from the region's focus on healthcare research and the availability of various treatment options.
Asia-Pacific: Growing Healthcare Awareness and Increasing Liver Disease Prevalence
In Asia-Pacific, the overt hepatic encephalopathy market is expanding due to growing healthcare awareness and the increasing prevalence of liver diseases. Countries like China and India are witnessing a rise in liver disease cases due to factors such as alcohol consumption and hepatitis infections. The improving healthcare facilities and the rising middle-class population with access to better medical care contribute to the market growth. The region's increasing investment in healthcare infrastructure and the growing focus on liver health present significant opportunities for market expansion.
Overt Hepatic Encephalopathy Market Key Player Analysis
In the Overt Hepatic Encephalopathy Market, a critical sector for treating complex liver-related brain dysfunction, the companies listed are pivotal in providing therapeutic solutions. Bausch Health Companies Inc. and Mallinckrodt Pharmaceuticals are significant players with a strong presence in the market, offering medications that are mainstays in treatment regimens. Their strategic positioning emphasizes research and development in therapies that improve patient outcomes.
ASKA Pharmaceutical Co., Ltd., and Ferring Pharmaceuticals Inc. contribute with their specialized focus on gastroenterology and innovative drug formulations, reflecting the market's need for effective and manageable treatments. Cosmo Pharmaceuticals N.V. and Lupin Limited are key players known for their global reach and commitment to expanding treatment options in the hepatic encephalopathy space.
Kaleido Biosciences and Kannalife Sciences Inc., with their cutting-edge research, are exploring novel therapeutic pathways, showcasing the industry's shift towards addressing underlying mechanisms of the disease. Umecrine Cognition AB and Norgine B.V., though smaller in comparison, offer unique solutions and are actively involved in advancing clinical research in this field.
Overt Hepatic Encephalopathy Industry Key Players
- ASKA Pharmaceutical Co., Ltd.
- Cosmo Pharmaceuticals N.V
- Lupin Limited.
- Kaleido Biosciences
- Kannalife Sciences Inc.
- Bausch Health Companies Inc.
- Ferring Pharmaceuticals Inc.
- Mallinckrodt Pharmaceuticals
- Umecrine Cognition AB.
- Norgine B.V.
- Abbott Laboratories
- QR Science and Technology Development Co.
Overt Hepatic Encephalopathy Market Recent Development
- In April 2023, Merck, the German multinational science and technology firm, and Eisai, the Japanese pharmaceutical corporation, released details regarding Phase 3 Trials to treat advanced Melanoma and metastatic Colorectal Cancer with orally accessible multiple receptor tyrosine-kinase inhibitors such as KEYTRUDA (pembrolizumab) and LENVIMA (lenvatinib), respectively.
- In March 2023, Bausch Health Companies Inc, a Canadian multinational specialty pharmaceutical company, recently made public announcements regarding an active trial using Rifaximin SSD tablets and Lactulose to treat Hepatic Encephalopathy directly. This trial is currently in Phase III clinical studies.
- In September 2022, GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of those suffering from liver disorders, announced they had purchased Versantis' clinical-stage Biopharmaceutical business with its three programs; ACLF (ACLF phase 2 ready), UCD infant program and early encephalopathy program (VS02-HE).
- In April 2022, Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc., the world's largest specialty pharmaceutical company, unveiled its treatments and preventive strategies for gastrointestinal illnesses. At SHM's Converge 2022 annual meet in Nashville in April Salix Pharmaceuticals displayed four posters describing XIFAXAN (rifaximin) AND RELISTO (methylnaltrexone bromide), respectively. Rifaximin can reduce emergency department service visits for Hepatic Encephalopathy Treatment Versus Lactulose All by Itself.
- In June 2021, Axcella, a global clinical-stage biotechnology company offering an innovative solution for managing complex diseases and improving overall health using endogenous metabolic modulator components, announced their initial activation and screening of patients for Phase 2 of AXA1665, an oral product targeting recurrent liver encephalopathy cases.
Report Scope
Report Features Description Market Value (2023) USD 52.16 million Forecast Revenue (2033) USD 112.3 million CAGR (2024-2032) 8.18% Base Year for Estimation 2023 Historic Period 2016-2023 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Type, (Cover, Overt), By Treatment (Lactulose, Antibiotics, Probiotics, Branched-Chain Amino Acids, Liver Transplantation, Others), By Application (Hospitals, Research Institutes, Clinics, Surgical Centers) Regional Analysis North America - The US, Canada, Rest of North America, Europe - Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe, Asia-Pacific - China, Japan, South Korea, India, New Zealand, Singapore, Thailand, Vietnam, Rest of Asia Pacific, Latin America - Brazil, Mexico, Rest of Latin America, Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa Competitive Landscape ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V, Lupin Limited., Kaleido Biosciences, Kannalife Sciences Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB., Norgine B.V., Abbott Laboratories, QR Science and Technology Development Co. Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
- 1. Executive Summary
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 1.4. Key Analysis
- 1.5. Key Findings by Major Segments
- 1.6. Top strategies by Major Players
- 2. Global Overt Hepatic Encephalopathy Market Overview
- 2.1. Overt Hepatic Encephalopathy Market Dynamics
- 2.1.1. Drivers
- 2.1.2. Opportunities
- 2.1.3. Restraints
- 2.1.4. Challenges
- 2.2. Macro-economic Factors
- 2.3. Regulatory Framework
- 2.4. Market Investment Feasibility Index
- 2.5. PEST Analysis
- 2.6. PORTER’S Five Force Analysis
- 2.7. Drivers & Restraints Impact Analysis
- 2.8. Industry Chain Analysis
- 2.9. Cost Structure Analysis
- 2.10. Marketing Strategy
- 2.11. Russia-Ukraine War Impact Analysis
- 2.12. Opportunity Map Analysis
- 2.13. Market Competition Scenario Analysis
- 2.14. Product Life Cycle Analysis
- 2.15. Opportunity Orbits
- 2.16. Manufacturer Intensity Map
- 2.17. Major Companies sales by Value & Volume
- 2.1. Overt Hepatic Encephalopathy Market Dynamics
- 3. Global Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, 2016-2032
- 3.1. Global Overt Hepatic Encephalopathy Market Analysis, 2016-2021
- 3.2. Global Overt Hepatic Encephalopathy Market Opportunity and Forecast, 2023-2032
- 3.3. Global Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 3.3.1. Global Overt Hepatic Encephalopathy Market Analysis by By Type: Introduction
- 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 3.3.3. Cover
- 3.3.4. Overt
- 3.4. Global Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 3.4.1. Global Overt Hepatic Encephalopathy Market Analysis by By Treatment: Introduction
- 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 3.4.3. Lactulose
- 3.4.4. Antibiotics
- 3.4.5. Probiotics
- 3.4.6. Branched-Chain Amino Acids
- 3.4.7. Liver Transplantation
- 3.4.8. Others
- 3.5. Global Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Application, 2016-2032
- 3.5.1. Global Overt Hepatic Encephalopathy Market Analysis by By Application: Introduction
- 3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Application, 2016-2032
- 3.5.3. Hospitals
- 3.5.4. Research Institutes
- 3.5.5. Clinics
- 3.5.6. Surgical Centers
- 4. North America Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, 2016-2032
- 4.1. North America Overt Hepatic Encephalopathy Market Analysis, 2016-2021
- 4.2. North America Overt Hepatic Encephalopathy Market Opportunity and Forecast, 2023-2032
- 4.3. North America Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 4.3.1. North America Overt Hepatic Encephalopathy Market Analysis by By Type: Introduction
- 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 4.3.3. Cover
- 4.3.4. Overt
- 4.4. North America Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 4.4.1. North America Overt Hepatic Encephalopathy Market Analysis by By Treatment: Introduction
- 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 4.4.3. Lactulose
- 4.4.4. Antibiotics
- 4.4.5. Probiotics
- 4.4.6. Branched-Chain Amino Acids
- 4.4.7. Liver Transplantation
- 4.4.8. Others
- 4.5. North America Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Application, 2016-2032
- 4.5.1. North America Overt Hepatic Encephalopathy Market Analysis by By Application: Introduction
- 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Application, 2016-2032
- 4.5.3. Hospitals
- 4.5.4. Research Institutes
- 4.5.5. Clinics
- 4.5.6. Surgical Centers
- 4.6. North America Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 4.6.1. North America Overt Hepatic Encephalopathy Market Analysis by Country : Introduction
- 4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 4.6.2.1. The US
- 4.6.2.2. Canada
- 4.6.2.3. Mexico
- 5. Western Europe Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, 2016-2032
- 5.1. Western Europe Overt Hepatic Encephalopathy Market Analysis, 2016-2021
- 5.2. Western Europe Overt Hepatic Encephalopathy Market Opportunity and Forecast, 2023-2032
- 5.3. Western Europe Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 5.3.1. Western Europe Overt Hepatic Encephalopathy Market Analysis by By Type: Introduction
- 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 5.3.3. Cover
- 5.3.4. Overt
- 5.4. Western Europe Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 5.4.1. Western Europe Overt Hepatic Encephalopathy Market Analysis by By Treatment: Introduction
- 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 5.4.3. Lactulose
- 5.4.4. Antibiotics
- 5.4.5. Probiotics
- 5.4.6. Branched-Chain Amino Acids
- 5.4.7. Liver Transplantation
- 5.4.8. Others
- 5.5. Western Europe Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Application, 2016-2032
- 5.5.1. Western Europe Overt Hepatic Encephalopathy Market Analysis by By Application: Introduction
- 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Application, 2016-2032
- 5.5.3. Hospitals
- 5.5.4. Research Institutes
- 5.5.5. Clinics
- 5.5.6. Surgical Centers
- 5.6. Western Europe Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 5.6.1. Western Europe Overt Hepatic Encephalopathy Market Analysis by Country : Introduction
- 5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 5.6.2.1. Germany
- 5.6.2.2. France
- 5.6.2.3. The UK
- 5.6.2.4. Spain
- 5.6.2.5. Italy
- 5.6.2.6. Portugal
- 5.6.2.7. Ireland
- 5.6.2.8. Austria
- 5.6.2.9. Switzerland
- 5.6.2.10. Benelux
- 5.6.2.11. Nordic
- 5.6.2.12. Rest of Western Europe
- 6. Eastern Europe Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, 2016-2032
- 6.1. Eastern Europe Overt Hepatic Encephalopathy Market Analysis, 2016-2021
- 6.2. Eastern Europe Overt Hepatic Encephalopathy Market Opportunity and Forecast, 2023-2032
- 6.3. Eastern Europe Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 6.3.1. Eastern Europe Overt Hepatic Encephalopathy Market Analysis by By Type: Introduction
- 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 6.3.3. Cover
- 6.3.4. Overt
- 6.4. Eastern Europe Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 6.4.1. Eastern Europe Overt Hepatic Encephalopathy Market Analysis by By Treatment: Introduction
- 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 6.4.3. Lactulose
- 6.4.4. Antibiotics
- 6.4.5. Probiotics
- 6.4.6. Branched-Chain Amino Acids
- 6.4.7. Liver Transplantation
- 6.4.8. Others
- 6.5. Eastern Europe Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Application, 2016-2032
- 6.5.1. Eastern Europe Overt Hepatic Encephalopathy Market Analysis by By Application: Introduction
- 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Application, 2016-2032
- 6.5.3. Hospitals
- 6.5.4. Research Institutes
- 6.5.5. Clinics
- 6.5.6. Surgical Centers
- 6.6. Eastern Europe Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 6.6.1. Eastern Europe Overt Hepatic Encephalopathy Market Analysis by Country : Introduction
- 6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 6.6.2.1. Russia
- 6.6.2.2. Poland
- 6.6.2.3. The Czech Republic
- 6.6.2.4. Greece
- 6.6.2.5. Rest of Eastern Europe
- 7. APAC Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, 2016-2032
- 7.1. APAC Overt Hepatic Encephalopathy Market Analysis, 2016-2021
- 7.2. APAC Overt Hepatic Encephalopathy Market Opportunity and Forecast, 2023-2032
- 7.3. APAC Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 7.3.1. APAC Overt Hepatic Encephalopathy Market Analysis by By Type: Introduction
- 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 7.3.3. Cover
- 7.3.4. Overt
- 7.4. APAC Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 7.4.1. APAC Overt Hepatic Encephalopathy Market Analysis by By Treatment: Introduction
- 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 7.4.3. Lactulose
- 7.4.4. Antibiotics
- 7.4.5. Probiotics
- 7.4.6. Branched-Chain Amino Acids
- 7.4.7. Liver Transplantation
- 7.4.8. Others
- 7.5. APAC Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Application, 2016-2032
- 7.5.1. APAC Overt Hepatic Encephalopathy Market Analysis by By Application: Introduction
- 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Application, 2016-2032
- 7.5.3. Hospitals
- 7.5.4. Research Institutes
- 7.5.5. Clinics
- 7.5.6. Surgical Centers
- 7.6. APAC Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 7.6.1. APAC Overt Hepatic Encephalopathy Market Analysis by Country : Introduction
- 7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 7.6.2.1. China
- 7.6.2.2. Japan
- 7.6.2.3. South Korea
- 7.6.2.4. India
- 7.6.2.5. Australia & New Zeland
- 7.6.2.6. Indonesia
- 7.6.2.7. Malaysia
- 7.6.2.8. Philippines
- 7.6.2.9. Singapore
- 7.6.2.10. Thailand
- 7.6.2.11. Vietnam
- 7.6.2.12. Rest of APAC
- 8. Latin America Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, 2016-2032
- 8.1. Latin America Overt Hepatic Encephalopathy Market Analysis, 2016-2021
- 8.2. Latin America Overt Hepatic Encephalopathy Market Opportunity and Forecast, 2023-2032
- 8.3. Latin America Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 8.3.1. Latin America Overt Hepatic Encephalopathy Market Analysis by By Type: Introduction
- 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 8.3.3. Cover
- 8.3.4. Overt
- 8.4. Latin America Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 8.4.1. Latin America Overt Hepatic Encephalopathy Market Analysis by By Treatment: Introduction
- 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 8.4.3. Lactulose
- 8.4.4. Antibiotics
- 8.4.5. Probiotics
- 8.4.6. Branched-Chain Amino Acids
- 8.4.7. Liver Transplantation
- 8.4.8. Others
- 8.5. Latin America Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Application, 2016-2032
- 8.5.1. Latin America Overt Hepatic Encephalopathy Market Analysis by By Application: Introduction
- 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Application, 2016-2032
- 8.5.3. Hospitals
- 8.5.4. Research Institutes
- 8.5.5. Clinics
- 8.5.6. Surgical Centers
- 8.6. Latin America Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 8.6.1. Latin America Overt Hepatic Encephalopathy Market Analysis by Country : Introduction
- 8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 8.6.2.1. Brazil
- 8.6.2.2. Colombia
- 8.6.2.3. Chile
- 8.6.2.4. Argentina
- 8.6.2.5. Costa Rica
- 8.6.2.6. Rest of Latin America
- 9. Middle East & Africa Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, 2016-2032
- 9.1. Middle East & Africa Overt Hepatic Encephalopathy Market Analysis, 2016-2021
- 9.2. Middle East & Africa Overt Hepatic Encephalopathy Market Opportunity and Forecast, 2023-2032
- 9.3. Middle East & Africa Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Type, 2016-2032
- 9.3.1. Middle East & Africa Overt Hepatic Encephalopathy Market Analysis by By Type: Introduction
- 9.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Type, 2016-2032
- 9.3.3. Cover
- 9.3.4. Overt
- 9.4. Middle East & Africa Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Treatment, 2016-2032
- 9.4.1. Middle East & Africa Overt Hepatic Encephalopathy Market Analysis by By Treatment: Introduction
- 9.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Treatment, 2016-2032
- 9.4.3. Lactulose
- 9.4.4. Antibiotics
- 9.4.5. Probiotics
- 9.4.6. Branched-Chain Amino Acids
- 9.4.7. Liver Transplantation
- 9.4.8. Others
- 9.5. Middle East & Africa Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By By Application, 2016-2032
- 9.5.1. Middle East & Africa Overt Hepatic Encephalopathy Market Analysis by By Application: Introduction
- 9.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Application, 2016-2032
- 9.5.3. Hospitals
- 9.5.4. Research Institutes
- 9.5.5. Clinics
- 9.5.6. Surgical Centers
- 9.6. Middle East & Africa Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 9.6.1. Middle East & Africa Overt Hepatic Encephalopathy Market Analysis by Country : Introduction
- 9.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 9.6.2.1. Algeria
- 9.6.2.2. Egypt
- 9.6.2.3. Israel
- 9.6.2.4. Kuwait
- 9.6.2.5. Nigeria
- 9.6.2.6. Saudi Arabia
- 9.6.2.7. South Africa
- 9.6.2.8. Turkey
- 9.6.2.9. The UAE
- 9.6.2.10. Rest of MEA
- 10. Global Overt Hepatic Encephalopathy Market Analysis, Opportunity and Forecast, By Region , 2016-2032
- 10.1. Global Overt Hepatic Encephalopathy Market Analysis by Region : Introduction
- 10.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
- 10.2.1. North America
- 10.2.2. Western Europe
- 10.2.3. Eastern Europe
- 10.2.4. APAC
- 10.2.5. Latin America
- 10.2.6. Middle East & Africa
- 11. Global Overt Hepatic Encephalopathy Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 11.1. Market Share Analysis
- 11.2. Company Profiles
- 11.3. ASKA Pharmaceutical Co., Ltd.
- 11.3.1. Company Overview
- 11.3.2. Financial Highlights
- 11.3.3. Product Portfolio
- 11.3.4. SWOT Analysis
- 11.3.5. Key Strategies and Developments
- 11.4. Cosmo Pharmaceuticals N.V
- 11.4.1. Company Overview
- 11.4.2. Financial Highlights
- 11.4.3. Product Portfolio
- 11.4.4. SWOT Analysis
- 11.4.5. Key Strategies and Developments
- 11.5. Lupin Limited.
- 11.5.1. Company Overview
- 11.5.2. Financial Highlights
- 11.5.3. Product Portfolio
- 11.5.4. SWOT Analysis
- 11.5.5. Key Strategies and Developments
- 11.6. Kaleido Biosciences
- 11.6.1. Company Overview
- 11.6.2. Financial Highlights
- 11.6.3. Product Portfolio
- 11.6.4. SWOT Analysis
- 11.6.5. Key Strategies and Developments
- 11.7. Kannalife Sciences Inc.
- 11.7.1. Company Overview
- 11.7.2. Financial Highlights
- 11.7.3. Product Portfolio
- 11.7.4. SWOT Analysis
- 11.7.5. Key Strategies and Developments
- 11.8. Bausch Health Companies Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Highlights
- 11.8.3. Product Portfolio
- 11.8.4. SWOT Analysis
- 11.8.5. Key Strategies and Developments
- 11.9. Ferring Pharmaceuticals Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Highlights
- 11.9.3. Product Portfolio
- 11.9.4. SWOT Analysis
- 11.9.5. Key Strategies and Developments
- 11.10. Mallinckrodt Pharmaceuticals
- 11.10.1. Company Overview
- 11.10.2. Financial Highlights
- 11.10.3. Product Portfolio
- 11.10.4. SWOT Analysis
- 11.10.5. Key Strategies and Developments
- 11.11. Umecrine Cognition AB.
- 11.11.1. Company Overview
- 11.11.2. Financial Highlights
- 11.11.3. Product Portfolio
- 11.11.4. SWOT Analysis
- 11.11.5. Key Strategies and Developments
- 11.12. Norgine B.V.
- 11.12.1. Company Overview
- 11.12.2. Financial Highlights
- 11.12.3. Product Portfolio
- 11.12.4. SWOT Analysis
- 11.12.5. Key Strategies and Developments
- 11.13.1. Company Overview
- 11.13.2. Financial Highlights
- 11.13.3. Product Portfolio
- 11.13.4. SWOT Analysis
- 11.13.5. Key Strategies and Developments
- 11.14. Abbott Laboratories
- 11.14.1. Company Overview
- 11.14.2. Financial Highlights
- 11.14.3. Product Portfolio
- 11.14.4. SWOT Analysis
- 11.14.5. Key Strategies and Developments
- 12. Assumptions and Acronyms
- 13. Research Methodology
- 14. Contact
"
- List of Figures
- "
- Figure 1: Global Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Type in 2022
- Figure 2: Global Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Type, 2016-2032
- Figure 3: Global Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 4: Global Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 5: Global Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Applicationin 2022
- Figure 6: Global Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Application, 2016-2032
- Figure 7: Global Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by Region in 2022
- Figure 8: Global Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by Region, 2016-2032
- Figure 9: Global Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Figure 10: Global Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Figure 11: Global Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 12: Global Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 13: Global Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Figure 14: Global Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Figure 15: Global Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 16: Global Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 17: Global Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Figure 18: Global Overt Hepatic Encephalopathy Market Market Share Comparison by Region (2016-2032)
- Figure 19: Global Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Figure 20: Global Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Figure 21: Global Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
- Figure 22: North America Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Typein 2022
- Figure 23: North America Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Type, 2016-2032
- Figure 24: North America Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 25: North America Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 26: North America Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Applicationin 2022
- Figure 27: North America Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Application, 2016-2032
- Figure 28: North America Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 29: North America Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 30: North America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Figure 31: North America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 32: North America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 33: North America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 34: North America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Figure 35: North America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 36: North America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 37: North America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 38: North America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Figure 39: North America Overt Hepatic Encephalopathy Market Market Share Comparison by Country (2016-2032)
- Figure 40: North America Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Figure 41: North America Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Figure 42: North America Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
- Figure 43: Western Europe Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Typein 2022
- Figure 44: Western Europe Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Type, 2016-2032
- Figure 45: Western Europe Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 46: Western Europe Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 47: Western Europe Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Applicationin 2022
- Figure 48: Western Europe Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Application, 2016-2032
- Figure 49: Western Europe Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 50: Western Europe Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 51: Western Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Figure 52: Western Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 53: Western Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 54: Western Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 55: Western Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Figure 56: Western Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 57: Western Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 58: Western Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 59: Western Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Figure 60: Western Europe Overt Hepatic Encephalopathy Market Market Share Comparison by Country (2016-2032)
- Figure 61: Western Europe Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Figure 62: Western Europe Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Figure 63: Western Europe Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
- Figure 64: Eastern Europe Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Typein 2022
- Figure 65: Eastern Europe Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Type, 2016-2032
- Figure 66: Eastern Europe Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 67: Eastern Europe Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 68: Eastern Europe Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Applicationin 2022
- Figure 69: Eastern Europe Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Application, 2016-2032
- Figure 70: Eastern Europe Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 71: Eastern Europe Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 72: Eastern Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Figure 73: Eastern Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 74: Eastern Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 75: Eastern Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 76: Eastern Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Figure 77: Eastern Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 78: Eastern Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 79: Eastern Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 80: Eastern Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Figure 81: Eastern Europe Overt Hepatic Encephalopathy Market Market Share Comparison by Country (2016-2032)
- Figure 82: Eastern Europe Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Figure 83: Eastern Europe Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Figure 84: Eastern Europe Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
- Figure 85: APAC Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Typein 2022
- Figure 86: APAC Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Type, 2016-2032
- Figure 87: APAC Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 88: APAC Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 89: APAC Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Applicationin 2022
- Figure 90: APAC Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Application, 2016-2032
- Figure 91: APAC Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 92: APAC Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 93: APAC Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Figure 94: APAC Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 95: APAC Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 96: APAC Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 97: APAC Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Figure 98: APAC Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 99: APAC Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 100: APAC Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 101: APAC Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Figure 102: APAC Overt Hepatic Encephalopathy Market Market Share Comparison by Country (2016-2032)
- Figure 103: APAC Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Figure 104: APAC Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Figure 105: APAC Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
- Figure 106: Latin America Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Typein 2022
- Figure 107: Latin America Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Type, 2016-2032
- Figure 108: Latin America Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 109: Latin America Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 110: Latin America Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Applicationin 2022
- Figure 111: Latin America Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Application, 2016-2032
- Figure 112: Latin America Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 113: Latin America Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 114: Latin America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Figure 115: Latin America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 116: Latin America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 117: Latin America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 118: Latin America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Figure 119: Latin America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 120: Latin America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 121: Latin America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 122: Latin America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Figure 123: Latin America Overt Hepatic Encephalopathy Market Market Share Comparison by Country (2016-2032)
- Figure 124: Latin America Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Figure 125: Latin America Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Figure 126: Latin America Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
- Figure 127: Middle East & Africa Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Typein 2022
- Figure 128: Middle East & Africa Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Type, 2016-2032
- Figure 129: Middle East & Africa Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Treatmentin 2022
- Figure 130: Middle East & Africa Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Treatment, 2016-2032
- Figure 131: Middle East & Africa Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by By Applicationin 2022
- Figure 132: Middle East & Africa Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by By Application, 2016-2032
- Figure 133: Middle East & Africa Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 134: Middle East & Africa Overt Hepatic Encephalopathy Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 135: Middle East & Africa Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Figure 136: Middle East & Africa Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 137: Middle East & Africa Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Figure 138: Middle East & Africa Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Figure 139: Middle East & Africa Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Figure 140: Middle East & Africa Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 141: Middle East & Africa Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Figure 142: Middle East & Africa Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Figure 143: Middle East & Africa Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Figure 144: Middle East & Africa Overt Hepatic Encephalopathy Market Market Share Comparison by Country (2016-2032)
- Figure 145: Middle East & Africa Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Figure 146: Middle East & Africa Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Figure 147: Middle East & Africa Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
"
- List of Tables
- "
- Table 1: Global Overt Hepatic Encephalopathy Market Market Comparison by By Type (2016-2032)
- Table 2: Global Overt Hepatic Encephalopathy Market Market Comparison by By Treatment (2016-2032)
- Table 3: Global Overt Hepatic Encephalopathy Market Market Comparison by By Application (2016-2032)
- Table 4: Global Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 5: Global Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Table 6: Global Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 7: Global Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 8: Global Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 9: Global Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Table 10: Global Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Table 11: Global Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 12: Global Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 13: Global Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Table 14: Global Overt Hepatic Encephalopathy Market Market Share Comparison by Region (2016-2032)
- Table 15: Global Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Table 16: Global Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Table 17: Global Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
- Table 18: North America Overt Hepatic Encephalopathy Market Market Comparison by By Treatment (2016-2032)
- Table 19: North America Overt Hepatic Encephalopathy Market Market Comparison by By Application (2016-2032)
- Table 20: North America Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 21: North America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Table 22: North America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 23: North America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 24: North America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 25: North America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Table 26: North America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 27: North America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 28: North America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 29: North America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Table 30: North America Overt Hepatic Encephalopathy Market Market Share Comparison by Country (2016-2032)
- Table 31: North America Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Table 32: North America Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Table 33: North America Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
- Table 34: Western Europe Overt Hepatic Encephalopathy Market Market Comparison by By Type (2016-2032)
- Table 35: Western Europe Overt Hepatic Encephalopathy Market Market Comparison by By Treatment (2016-2032)
- Table 36: Western Europe Overt Hepatic Encephalopathy Market Market Comparison by By Application (2016-2032)
- Table 37: Western Europe Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 38: Western Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Table 39: Western Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 40: Western Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 41: Western Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 42: Western Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Table 43: Western Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 44: Western Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 45: Western Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 46: Western Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Table 47: Western Europe Overt Hepatic Encephalopathy Market Market Share Comparison by Country (2016-2032)
- Table 48: Western Europe Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Table 49: Western Europe Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Table 50: Western Europe Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
- Table 51: Eastern Europe Overt Hepatic Encephalopathy Market Market Comparison by By Type (2016-2032)
- Table 52: Eastern Europe Overt Hepatic Encephalopathy Market Market Comparison by By Treatment (2016-2032)
- Table 53: Eastern Europe Overt Hepatic Encephalopathy Market Market Comparison by By Application (2016-2032)
- Table 54: Eastern Europe Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 55: Eastern Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Table 56: Eastern Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 57: Eastern Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 58: Eastern Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 59: Eastern Europe Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Table 60: Eastern Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 61: Eastern Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 62: Eastern Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 63: Eastern Europe Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Table 64: Eastern Europe Overt Hepatic Encephalopathy Market Market Share Comparison by Country (2016-2032)
- Table 65: Eastern Europe Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Table 66: Eastern Europe Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Table 67: Eastern Europe Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
- Table 68: APAC Overt Hepatic Encephalopathy Market Market Comparison by By Type (2016-2032)
- Table 69: APAC Overt Hepatic Encephalopathy Market Market Comparison by By Treatment (2016-2032)
- Table 70: APAC Overt Hepatic Encephalopathy Market Market Comparison by By Application (2016-2032)
- Table 71: APAC Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 72: APAC Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Table 73: APAC Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 74: APAC Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 75: APAC Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 76: APAC Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Table 77: APAC Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 78: APAC Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 79: APAC Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 80: APAC Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Table 81: APAC Overt Hepatic Encephalopathy Market Market Share Comparison by Country (2016-2032)
- Table 82: APAC Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Table 83: APAC Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Table 84: APAC Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
- Table 85: Latin America Overt Hepatic Encephalopathy Market Market Comparison by By Type (2016-2032)
- Table 86: Latin America Overt Hepatic Encephalopathy Market Market Comparison by By Treatment (2016-2032)
- Table 87: Latin America Overt Hepatic Encephalopathy Market Market Comparison by By Application (2016-2032)
- Table 88: Latin America Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 89: Latin America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Table 90: Latin America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 91: Latin America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 92: Latin America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 93: Latin America Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Table 94: Latin America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 95: Latin America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 96: Latin America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 97: Latin America Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Table 98: Latin America Overt Hepatic Encephalopathy Market Market Share Comparison by Country (2016-2032)
- Table 99: Latin America Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Table 100: Latin America Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Table 101: Latin America Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
- Table 102: Middle East & Africa Overt Hepatic Encephalopathy Market Market Comparison by By Type (2016-2032)
- Table 103: Middle East & Africa Overt Hepatic Encephalopathy Market Market Comparison by By Treatment (2016-2032)
- Table 104: Middle East & Africa Overt Hepatic Encephalopathy Market Market Comparison by By Application (2016-2032)
- Table 105: Middle East & Africa Overt Hepatic Encephalopathy Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 106: Middle East & Africa Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) (2016-2032)
- Table 107: Middle East & Africa Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 108: Middle East & Africa Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Type (2016-2032)
- Table 109: Middle East & Africa Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Treatment (2016-2032)
- Table 110: Middle East & Africa Overt Hepatic Encephalopathy Market Market Revenue (US$ Mn) Comparison by By Application (2016-2032)
- Table 111: Middle East & Africa Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 112: Middle East & Africa Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Type (2016-2032)
- Table 113: Middle East & Africa Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Treatment (2016-2032)
- Table 114: Middle East & Africa Overt Hepatic Encephalopathy Market Market Y-o-Y Growth Rate Comparison by By Application (2016-2032)
- Table 115: Middle East & Africa Overt Hepatic Encephalopathy Market Market Share Comparison by Country (2016-2032)
- Table 116: Middle East & Africa Overt Hepatic Encephalopathy Market Market Share Comparison by By Type (2016-2032)
- Table 117: Middle East & Africa Overt Hepatic Encephalopathy Market Market Share Comparison by By Treatment (2016-2032)
- Table 118: Middle East & Africa Overt Hepatic Encephalopathy Market Market Share Comparison by By Application (2016-2032)
- 1. Executive Summary
-
- ASKA Pharmaceutical Co., Ltd.
- Cosmo Pharmaceuticals N.V
- Lupin Limited.
- Kaleido Biosciences
- Kannalife Sciences Inc.
- Bausch Health Companies Inc.
- Ferring Pharmaceuticals Inc.
- Mallinckrodt Pharmaceuticals
- Umecrine Cognition AB.
- Norgine B.V.
- Abbott Laboratories
- QR Science and Technology Development Co.
Our Clients
View Our Licence Options
